Ce document numérisé est le fruit d'un long travail approuvé par le ...

182
103. Johnson WG, Morrone LC, Furman Y. Genetics of ALS : Analysis of 68
pedigrees. Neurology 1988; 38 (Suppl 1) : 174.
104. Jokelainen M. The epidemiology of amyotrophie lateral sclerosis in
Finland. J. Neurol Sci 1976; 29: 53-63.
105. Julien JP. Rôle des neurofilaments dans la sclérose latérale amyotrophique.
Médecine/ Sciences 1997: 13/4: 549-556.
106. Kanner BI, Schuldiner S. Mecanism of transport and storage of
neurotransmitters. CRC Crit Rev Biochem 1987; 22: 1-38.
107. Kantarijian AD. A syndrome resembling amyotrophie lateral sclerosis
following chronic mercurialism. Neurology 1961; 11 : 639-644.
108. Kasarskis EJ and the BDNF Study Group (Phase Ill) A controlled trial of
recombinant methionyl human BDNF in ALS. neurology 1999; 52: 1427-1433.
109. Kasarskis EJ , Neville HE. Management of ALS : Nutritional care :
Neurology 1996; 47 (Suppl 2) : 118-120.
110. Kew JJM, Leigh PN, Playford ED, et aL Cortical function in amyotrophie
lateral sclerosis. A positron emission tomography study. Brain 1993 ; 119 : 655­
680.
111. Kimura F, Smith RG, Delbono 0, et al. Immunoglobulins from patients
with amyotrophie lateral sclerosis recognize L-type voltage-gated calcium
channel alpha 1 subunit. Ann Neurol 1994; 35: 164-171.
112. Kondo K. Population dynamics of motor neuron disease. In Tsubaki T,
Toyokura Y (eds). Amyotrophie lateral sclerosis. Baltimore, University Park
Press, 1979.
113. Kondo K, Tsubaki T. Case-control studies of motor neuron disease.
Associations with mechanical injuries. Arch Neurol 1981 ; 38: 220-226.
114. Kostic V, Jackson-Lewis V, de Bilbao F, et aL Bcl-2 : prolonging life in a
transgenic mouse model of familial amyotrophie lateral sclerosis. Science 1997 ;
277 : 559-562.
115. Kroemer G; The proto-oncogne Bel-Z and its role in regulating apoptosis.
Nat Med 1997 ; 3: 614-620.
116. Kuroda Y, Sugihara H. Autopsy report of MTLV-1 associated myelopathy
presenting with ALS-like manifestations. J. Neurol Sci 1991 ; 106 : 199-205.